Ilumya Injectable Product
ApprovedSmall molecule
Ilumya Injectable Product is one of 31 small molecule programs targeting Psoriasis. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
605 competitors in Psoriasis
#DrugCompanyPhaseTrials
1Stelara
Johnson & JohnsonPreclinical
Ilumya Injectable Product
PPsoriasis Treatment Center of Central New Jersey
Approved
Taltz
Eli LillyPreclinical
Bimzelx
UCBPreclinical
Humira
CCelltrion
Preclinical
Ilumya
Sun Pharmaceutical Industries, Inc.Preclinical
Raptiva
RochePreclinical
Remicade
OOrganon and Co
Preclinical
Siliq
BBausch Health Americas, Inc.
Preclinical
Victoza
Novo NordiskPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ilumya Injectable Product. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details